Design of a prospective neonatal cohort study of homozygous and double heterozygous Factor V Leiden and Factor II G20210A

Abstract.

Background: Factor V Leiden (FVL) and Factor II (FII) G20210A represent common risk factors for thromboembolic (TE) events. In children, both venous and arterial TE-events have been associated with the presence of FVL and FII G20210A. In most heterozygous children with TE-events other prothrombotic factors can usually be identified. Case reports of children with homozygous FVL, including 3 patients described here, suggest that this genotype may convey a particulary high risk. However, prospective data about the type and frequency of TE-events in such children are lacking. Study design: We have initiated a prospective neonatal cohort study for the homozygous and double heterozygous genotypes for FVL and FII G20210A. The probands and the heterozygous controls are identified by neonatal screening that involves > 98 % of the children born in Berlin and are followed up in a special out-patient clinic to document details of the clinical history, developmental parameters and the occurrence of TE-events. Conclusions: This study will provide controlled and unbiased information about the clinical significance of the homozygous and double heterozygous genotypes of these mutations.

Hintergrund: Die Faktor V Leiden (FVL) und die FII G20210A Mutationen stellen bekannte Risikofaktoren für thromboembolische (TE-) Ereignisse dar. Im Kindesalter sind sowohl venöse als auch arterielle TE-Ereignisse mit dem Vorkommen der FVL oder der FII G20210A Mutation assoziiert. Bei heterozygoten Kindern mit TE-Ereignissen können meist weitere prothrombotische Faktoren identifiziert werden. Mehrere Fallberichte lassen für Kinder mit homozygotem Genotyp für FVL ein höheres Risiko vermuten. Prospektive Daten über Häufigkeit und Typ von TE-Ereignissen bei solchen Kindern liegen jedoch bislang nicht vor. Studiendesign: Wir initiierten eine prospektive neonatale Kohortenstudie zum homozygoten und doppelt heterozygoten Genotyp für die FVL und die FII G20210A Mutationen. Die Probanden und die heterozygoten Kontrollen werden im Rahmen des neonatalen Screening identifiziert, welches > 98 % der Neugeborenen in Berlin umfasst. Die Follow-up-Untersuchungen beinhalten die Dokumentation der Anamnese, des entwicklungsneurologischen und allgemein-pädiatrischen Untersuchungsbefundes und des Auftretens von TE-Ereignissen. Schlussfolgerung: Diese Studie wird kontrollierte und prospektive Informationen zur klinischen Bedeutung des homozygoten und des doppelt heterozygoten Genotyps für diese Mutationen liefern.

Thrombosis in children - Factor V Leiden - Factor II G20210A

Thrombose bei Kindern - Faktor V Leiden - Faktor II G20210A

Literatur

• 01 Andrew  M, Montgomery  R R. Acquired Disorders of Hemostasis. In: Nathan D, Orkin S (eds). Nathan and Oski's Hematology of Infancy and Childhood (Vol. 2). WB Saunders Company, Philadelphia; 1998:
• 02 Bertina  R M, Koeleman  B P, Koster  T, Rosendaal  F R, Dirven  R J, de Ronde  H, van der Velden  P A, Reitsma  P H. Mutation in blood coagulation factor V associated with resistance to activated protein C.  Nature. 1994;;  6475 64-67
• 03 Corral  J, Gonzalez Conejero  R, Lozano  M L, Rivera  J, Heras  I, Vicente  V. The venous thrombosis risk factor 20210 A allele of the prothrombin gene is not a major risk factor for arterial thrombotic disease.  Br J Haematol. 1997;;  2 304-307
• 04 deVeber  G, Monagle  P, Chan  A, MacGregor  D, Curtis  R, Lee  S, Vegh  P, Adams  M, Marzinotto  V, Leaker  M, Massicotte  M P, Lillicrap  D, Andrew  M. Prothrombotic disorders in infants and children with cerebral thromboembolism.  Arch Neurol. 1998;;  12 1539-1543
• 05 Ganesan  V, Kelsey  H, Cookson  J, Osborn  A, Kirkham  F J. Activated protein C resistance in childhood stroke.  Lancet. 1996;;  8996 260
• 06 Gopel  W, Kim  D, Gortner  L. Prothrombotic mutations as a risk factor for preterm birth.  Lancet. 1999;;  353 1411-1412
• 07 Gruppo  R, Glueck  C J, Wall  E, Roy  D, Wang  P. Legg-Perthes disease in three siblings, two heterozygous and one homozygous for the factor V Leiden mutation.  J Pediatr. 1998;;  5 885-888
• 08 Gurakan  F, Gurgey  A, Bakkaloglu  A, Kocak  N. Homozygous factor V Leiden mutation in a child with Budd-Chiari syndrome.  J Pediatr Gastroenterol Nutr. 1999;;  5 516-517
• 09 Gurgey  A. Clinical manifestations in thrombotic children with factor V Leiden mutation.  Pediatr Hematol Oncol. 1999;;  3 233-237
• 10 Hagstrom  J N, Walter  J, Bluebond Langner  R, Amatniek  J C, Manno  C S, High  K A. Prevalence of the factor V leiden mutation in children and neonates with thromboembolic disease.  J Pediatr. 1998;;  6 777-781
• 11 Heller  C, Becker  S, Scharrer  I, Kreuz  W. Prothrombotic risk factors in childhood stroke and venous thrombosis. Eur J Pediatr 1999:: S117-S121
• 12 Heresbach  D, Pagenault  M, Gueret  P, Crenn  P, Heresbach-Le Berre  N, Malledant  Y, Fauchet  R, Horellou  M H, Silver  J, Messing  B, Bretagne  J F. Leiden factor V mutation in four patients with small bowel infarctions.  Gastroenterology. 1997;;  1 322-325
• 13 Junker  R, Koch  H G, Auberger  K, Munchow  N, Ehrenforth  S, Nowak-Göttl  U. Prothrombin G20210A Gene Mutation and Further Prothrombotic Risk Factors in Childhood Thrombophilia.  Arterioscler Thromb Vasc Biol. 1999;;  10 2568-2572
• 14 Longstreth  W T Jr, Rosendaal  F R, Siscovick  D S, Vos  H L, Schwartz  S M, Psaty  B M, Raghunathan  T E, Koepsell  T D, Reitsma  P H. Risk of stroke in young women and two prothrombotic mutations: factor V Leiden and prothrombin gene variant (G20210A).  Stroke. 1998;;  3 577-580
• 15 Nowak-Gottl  U, Dubbers  A, Kececioglu  D, Koch  H G, Kotthoff  S, Runde  J, Vielhaber  H. Factor V Leiden, protein C, and lipoprotein (a) in catheter-related thrombosis in childhood: a prospective study.  J Pediatr. 1997;;  4 608-612
• 16 Nowak-Gottl  U, Koch  H G, Aschka  I, Kohlhase  B, Vielhaber  H, Kurlemann  G, Oleszcuk Raschke  K, Kehl  H G, Jurgens  H, Schneppenheim  R. Resistance to activated protein C (APCR) in children with venous or arterial thromboembolism.  Br J Haematol. 1996;;  4 992-998
• 17 Nowak-Gottl  U, Strater  R, Dubbers  A, Oleszuk-Raschke  K, Vielhaber  H. Ischaemic stroke in infancy and childhood: role of the Arg506 to Gln mutation in the factor V gene.  Blood Coagul Fibrinolysis. 1996;;  7 684-688
• 18 Poort  S R, Rosendaal  F R, Reitsma  P H, Bertina  R M. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis.  Blood. 1996;;  10 3698-3703
• 19 Ridker  P M, Hennekens  C H, Lindpaintner  K, Stampfer  M J, Eisenberg  P R, Miletich  J P. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men.  N Engl J Med. 1995;;  14 912-917
• 20 Rosendaal  F R, Koster  T, Vandenbroucke  J P, Reitsma  P H. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance).  Blood. 1995;;  6 1504-1508
• 21 Simioni  P, de Ronde  H, Prandoni  P, Saladini  M, Bertina  R M, Girolami  A. Ischemic stroke in young patients with activated protein C resistance. A report of three cases belonging to three different kindreds.  Stroke. 1995;;  5 885-890
• 22 Svensson  P J, Dahlback  B. Resistance to activated protein C as a basis for venous thrombosis.  N Engl J Med. 1994;;  8 517-522
• 23 Uttenreuther Fischer  M M, Vetter  B, Hellmann  C, Otting  U, Ziemer  S, Hausdorf  G, Gaedicke  G, Kulozik  A E. Paediatric thrombo-embolism: the influence of non-genetic factors and the role of activated protein C resistance and protein C deficiency.  Eur J Pediatr. 1997;;  4 277-281
• 24 Zenz  W, Bodo  Z, Plotho  J, Streif  W, Male  C, Bernert  G, Rauter  L, Ebetsberger  G, Kaltenbrunner  K, Kurnik  P, Lischka  A, Paky  F, Ploier  R, Hofler  G, Mannhalter  C, Muntean  W. Factor V Leiden and prothrombin gene G 20210 A variant in children with ischemic stroke.  Thromb Haemost. 1998;;  5 763-766